StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a note issued to investors on Thursday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Trading Up 0.5 %

NASDAQ:CHEK opened at $2.22 on Thursday. The company’s 50 day moving average is $2.26 and its two-hundred day moving average is $2.49. The company has a market cap of $12.99 million, a PE ratio of -0.74 and a beta of 0.45. Check-Cap has a twelve month low of $1.30 and a twelve month high of $4.63.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.